Jan 6, 2026, 13:39
JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
JAMA Neurology shared on LinkedIn:
”In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy.
Read the full article in JAMA.
Article: Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis. A Randomized Clinical Trial
Authors: Shuhei Okazaki, Kanta Tanaka, Yukako Yazawa et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 9, 2026, 07:31DHR-Sponsored Training Programme at ICMR-CRMCH Week 2 – Day 4 – ICMR-NIRBID
-
Jul 9, 2026, 06:03Barbara Adams Krolak: ISTH Launches Global Women’s Health Hub
-
Jul 9, 2026, 05:49Abdul Mannan: A Low Platelet Count is not Always a Bone Marrow Problem
-
Jul 9, 2026, 05:41Julieta Rosales: Management of Tandem Strokes – To Stent or Not to Stent?
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection